At the tip of every Olympus duodenoscope sits a tiny mechanical part called the elevator mechanism. It is the single most studied defect in medical device history — and it is the reason Olympus scopes have been linked to deadly superbug outbreaks at major hospitals across the United States.
This page explains exactly what the defect is, what Olympus knew about it and when, why the 2016 scope redesign did not solve the problem, and what the June 2025 FDA import alert means today for patients who have been seriously hurt.
At the very tip of an Olympus duodenoscope is a small, hinged lever called the elevator mechanism. It is no bigger than a pencil eraser. Its job is to steer wires, catheters, and other small tools through the working channel of the scope during an ERCP procedure. Without it, the procedure could not be performed.
But that same lever also creates tight seams, a small enclosed channel, and moving parts that brushes and disinfectant cannot fully reach. During a procedure, biological material — including blood, tissue, bile, and bacteria from the patient's digestive tract — works its way into those crevices. When the scope is then cleaned and reused on the next patient, some of that material survives.
The FDA has described this as a fundamental problem with the physical design of the device, not a problem that can be solved by training hospital staff to clean better. Multiple independent studies have confirmed that even after full cleaning and high-level disinfection performed exactly according to Olympus's own instructions, bacteria can be cultured from the elevator channel.
Standard high-level disinfection relies on liquid chemical sterilants soaking the surfaces of the scope. But the elevator mechanism's tiny crevices and moving parts physically block the disinfectant from reaching every surface. Even scopes that pass a full reprocessing cycle can still carry live, drug-resistant bacteria.
This is not a hygiene problem hospitals can scrub their way out of. It is a product problem — and that is what makes it grounds for a product liability case against Olympus.
The defect is most severe in duodenoscopes used for ERCP procedures. However, the FDA's June 2025 import alert covered 58 different Olympus endoscope models, which means the concern extends well beyond duodenoscopes alone. If you had any endoscopic procedure involving an Olympus scope since 2012 and developed a serious infection afterward, it is worth reviewing the full list of affected procedures.
The contamination crisis did not take anyone inside Olympus by surprise. By the time the FDA publicly warned the medical community in 2015, Olympus had already received reports of superbug outbreaks linked to its scopes years earlier — and, according to federal prosecutors, had failed to pass those reports along to U.S. regulators.
An outbreak linked to contaminated Olympus duodenoscopes was identified at a hospital in the Netherlands. Olympus was informed. The U.S. Department of Justice later found that the outbreak was not reported to the FDA in the United States, even though federal law required medical device makers to report this kind of adverse event when it suggested a device could cause serious injury or death.
Additional outbreaks were linked to Olympus scopes in Europe and the United States, including at Virginia Mason Medical Center in Seattle. At Virginia Mason, at least 39 patients were infected and 18 later died after ERCP procedures using Olympus duodenoscopes. Investigators eventually traced the outbreak back to the elevator channel of the scopes themselves.
UCLA's Ronald Reagan Medical Center publicly announced that 179 patients may have been exposed to CRE superbugs through contaminated Olympus duodenoscopes. Seven patients were confirmed infected. Two died. Cedars-Sinai announced a separate exposure of roughly 68 patients shortly after. Both cases made national news and forced the FDA to act publicly.
The FDA issued a formal Safety Communication titled Supplemental Measures to Enhance Duodenoscope Reprocessing, telling hospitals that standard cleaning was not enough. The same month, the U.S. Senate's Health, Education, Labor and Pensions (HELP) Committee released a report called Preventable Tragedies: Superbugs and How Ineffective Monitoring of Medical Device Safety Fails Patients. That report documented that Olympus had known about the problem for years and had not shared the information with U.S. hospitals or regulators.
In January 2016, Olympus announced a voluntary recall of its TJF-Q180V duodenoscope — the flagship model at the center of the UCLA and Seattle outbreaks — and released a redesigned version. The redesign replaced the elevator mechanism's rubber O-ring seal with a newer sealed design meant to block bacteria from entering the elevator channel.
On paper, this was the fix. In practice, outbreaks kept happening.
Independent post-market research and FDA surveillance found that even redesigned duodenoscopes continued to harbor dangerous bacteria after full reprocessing. The elevator channel was still extremely difficult to clean. The redesign improved certain parts of the scope but did not eliminate the underlying problem: a reusable medical device with small, complex internal structures that standard disinfection chemistry cannot consistently reach.
By 2019, the FDA had asked all duodenoscope manufacturers — not just Olympus — to transition to fully disposable scope caps or fully single-use scopes. The fact that the FDA ultimately pushed the industry toward single-use designs is itself an acknowledgment that reusable scopes, including the redesigned Olympus models, could not be reliably cleaned.
If you had an Olympus scope procedure after the 2016 redesign and still developed a serious infection, you are not alone — and the redesign does not protect Olympus from responsibility. The redesigned scope was still a reusable scope with the same basic limitations, and continued outbreaks are well-documented in FDA adverse event reports.
On December 10, 2018, the United States Department of Justice announced that Olympus Medical Systems Corporation — the Japanese subsidiary responsible for the duodenoscope line — had agreed to plead guilty and pay $85 million for failing to file required reports with the FDA about serious infection outbreaks tied to its scopes.
Under U.S. law, medical device manufacturers have to tell the FDA within 30 days when they learn that one of their devices may have caused or contributed to a serious injury or death. Federal prosecutors found that Olympus failed to file these reports for the 2012 Dutch outbreak and other early warning signs. In pleading guilty, Olympus admitted that this failure kept U.S. hospitals and regulators from learning about the dangers of its scopes for years longer than they should have.
The $85 million penalty was paid to the federal government, not to individual patients. Its importance for patients lies somewhere else: it is a public, corporate admission that Olympus failed to warn. That admission is part of the record in civil cases brought by patients harmed by the same scopes.
For a more detailed breakdown of FDA actions since 2015, see the page on FDA warnings and recalls.
On June 24, 2025, the FDA issued an import alert that effectively blocks 58 Olympus endoscope models from entering the United States. An import alert is one of the strongest tools the FDA has against a foreign medical device maker: U.S. Customs and Border Protection is authorized to detain every listed product at the border, and the manufacturer has to prove the product is safe before any of it can be released.
The 2025 import alert was not just about contamination risk on paper. It was tied to specific, documented failures by Olympus to meet the FDA's standards for manufacturing quality, device safety, and adverse-event reporting. In other words, more than ten years after the first outbreaks and seven years after the DOJ guilty plea, U.S. regulators still did not trust Olympus to police itself.
The import alert is important context for anyone considering a case today. It means the federal government has formally recognized, on the record, that Olympus scopes represent a serious enough risk to block from the market. That public finding can be used as part of the evidence in a civil case for patients who were harmed before the alert was issued.
Plain-English answers to the most common questions we hear from patients and families calling about Olympus scope infections.
The elevator mechanism at the tip of the duodenoscope creates tiny crevices and a small enclosed channel that trap blood, tissue, bile, and bacteria during a procedure. Standard cleaning and high-level disinfection cannot reliably remove this biological material. Even when a hospital follows Olympus's own cleaning instructions exactly, dangerous pathogens can survive inside the scope and be passed to the next patient. Federal investigators and independent researchers have identified this as a design defect — a flaw built into the scope itself, not a mistake by hospital staff.
Both can play a role, but the FDA and federal prosecutors have repeatedly concluded that the core problem is the scope's design. Hospitals that followed Olympus's cleaning instructions step by step still ended up with contaminated scopes and dead patients. That is what sets this crisis apart from ordinary hospital-acquired infection cases. When a product cannot be used safely even when instructions are followed, the manufacturer can be held responsible under product liability law. Hospitals can still share the blame when they cut corners on cleaning, but the scope itself is the root cause in most documented outbreaks.
Public records show that Olympus received internal warnings about superbug outbreaks linked to its duodenoscopes as early as 2012, including an outbreak at a hospital in the Netherlands. In 2018, an Olympus subsidiary pled guilty to federal charges for failing to report those outbreaks to the FDA as required by U.S. law. The company paid an $85 million penalty. This guilty plea is part of the public record and can be used as evidence in civil lawsuits.
Possibly, yes. Every state has its own time limit for filing a product liability or injury case — called a statute of limitations — and those limits are often measured from the date the patient discovered (or reasonably should have discovered) that a contaminated scope caused their infection. Because many patients were never told the scope was the source, the clock may not have started when you think it did. The only way to know if your case is still in time is to speak with an attorney about your specific facts. A free case review costs you nothing.
Every factual claim on this page is supported by a verifiable public source. Click any source below to read the original.
If you or a loved one developed a serious infection after an endoscopic procedure, the design defect in Olympus scopes may be why. A free case review with our team is confidential and costs you nothing. No Fees Unless We Recover Money for You.
